Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran in Subjects With Elevated Lipoprotein(a)
NCT04270760Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 7
01
Overview
A Phase 2 trial of olpasiran in atherosclerotic cardiovascular disease (ASCVD), elevated lipoprotein(a) (Lp(a)), sponsored by Amgen. Started Jul 2020; status: completed.
02
Drugs
olpasiran
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT04270760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270760.